Can trazodone be co‑administered with benzodiazepines?

Can Trazodone Be Combined with Benzodiazepines?

Trazodone can be co-administered with benzodiazepines from a pharmacokinetic standpoint—there are no absolute contraindications—but this combination significantly increases risks of excessive sedation, falls, respiratory depression, and mortality, particularly in older adults and those taking concurrent opioids. The American Academy of Sleep Medicine explicitly warns against combining benzodiazepine receptor agonist hypnotics with other sedatives due to additive adverse effects. 1

Pharmacokinetic Safety Profile

• Co-administration does not alter trazodone metabolism: A study of 43 depressed patients receiving trazodone 150 mg at bedtime found that concurrent benzodiazepine use did not affect plasma concentrations of trazodone or its active metabolite m-chlorophenylpiperazine (mCPP), nor did it change the mCPP/trazodone ratio. 2

• Linear kinetics are maintained: When trazodone doses were increased from 150 mg to 300 mg in patients taking benzodiazepines, neither plasma concentration/dose ratios nor metabolite ratios changed significantly, confirming that benzodiazepines do not interfere with trazodone's pharmacokinetics. 2

Critical Safety Concerns with Combination Therapy

Additive CNS Depression

• All sedative-hypnotics have additive psychomotor effects: When trazodone is combined with benzodiazepines or other CNS depressants, the risk of excessive daytime sedation, impaired driving ability, falls, and respiratory depression increases substantially. 1

• Fatal overdoses documented: Death from overdose has occurred in patients ingesting trazodone concurrently with CNS depressant drugs including benzodiazepines (diazepam, chlordiazepoxide). The FDA label explicitly warns about this risk. 3

Mortality Risk in Specific Populations

• Dramatically increased mortality with concurrent opioids: In Medicare beneficiaries ≥65 years taking opioids, benzodiazepines combined with any hypnotic (including trazodone) showed out-of-hospital mortality of 21.0/1,000 person-years versus 8.1/1,000 for trazodone alone (HR 3.02,95% CI 1.83–4.97, p<0.001). 4

• Orthostatic hypotension and falls: In hypertensive older adults, trazodone users showed significantly greater systolic BP drops immediately after standing (23.8 vs 14.3 mmHg, p=0.037) and had a 58.3% incidence of syncope/falls versus 21.2% in non-users (p=0.001). Adding benzodiazepines would compound this risk. 5

When Combination May Be Considered

Benzodiazepine Tapering Protocols

• Trazodone as benzodiazepine replacement: In a controlled study of benzodiazepine-dependent patients, trazodone 100 mg three times daily was used during progressive benzodiazepine taper over 2–4 weeks, with all patients remaining benzodiazepine-free at 1-year follow-up and no evidence of trazodone abuse. 6

• Short-term overlap during discontinuation: A double-blind study showed that trazodone pretreatment for 1–2 weeks before benzodiazepine taper (25% per week) resulted in 67% of patients being benzodiazepine-free at 5 weeks post-taper versus 31% with placebo (p<0.03). 7

• Gradual taper is mandatory: The FDA label for trazodone emphasizes gradually reducing dosage rather than abrupt discontinuation to avoid adverse reactions. 3

Clinical Algorithm for Decision-Making

Step 1: Assess the Clinical Indication

• If the goal is insomnia treatment: Do NOT combine. The American Academy of Sleep Medicine recommends against using trazodone for insomnia due to insufficient efficacy data, and explicitly warns against combining benzodiazepine receptor agonists with other sedatives. 1

• If the goal is benzodiazepine discontinuation: Combination is appropriate ONLY during a structured taper protocol lasting 2–4 weeks, with trazodone 100 mg three times daily (total 300 mg/day) while benzodiazepines are reduced by 25% weekly. 6, 7

Step 2: Screen for High-Risk Factors

Absolute contraindications to combination:

• Concurrent opioid use (mortality HR 3.02 for benzodiazepines + any hypnotic vs trazodone alone) 4
• Age ≥75 years with hypertension (58.3% syncope/fall rate with trazodone alone) 5
• History of respiratory depression or sleep apnea 3
• Alcohol use disorder (fatal overdoses documented) 3

Step 3: If Combination Is Necessary

• Start trazodone at 100 mg three times daily (not the typical 150 mg bedtime dose for depression) during benzodiazepine taper. 6

• Reduce benzodiazepine by 25% per week over 2–4 weeks while maintaining trazodone. 6, 7

• Monitor weekly for: withdrawal symptoms (anxiety, insomnia rebound), excessive sedation, orthostatic hypotension, falls, and cognitive impairment. 6, 7

• Discontinue benzodiazepine completely before considering trazodone dose reduction. 6

• Taper trazodone gradually after benzodiazepine discontinuation; in follow-up studies, doses were reduced from 300 mg to 185 mg over 1 year (p=0.003). 6

Evidence-Based Alternatives to Combination Therapy

For Insomnia Without Benzodiazepine Dependence

• First-line: Cognitive Behavioral Therapy for Insomnia (CBT-I) demonstrates superior long-term efficacy compared to any medication. 1, 8

• Pharmacotherapy if CBT-I insufficient:

  • Sleep-onset insomnia: Ramelteon 8 mg (zero addiction potential) or zaleplon 5–10 mg 1, 8
  • Sleep-maintenance insomnia: Low-dose doxepin 3–6 mg (reduces wake-after-sleep-onset by 22–23 minutes, HR comparable to placebo) 9

• Avoid trazodone for primary insomnia: The American Academy of Sleep Medicine found no differences in sleep efficiency, latency, total sleep time, or wake-after-sleep-onset compared to placebo. 1

For Benzodiazepine-Dependent Patients

• Trazodone monotherapy after taper completion: All 10 patients in one study remained benzodiazepine-free at 1 year on trazodone alone (mean dose 185 mg), with Hamilton Anxiety Scale scores improving from 12.3 to 5.4 (p=0.002). 6

Common Pitfalls to Avoid

• Do not combine for routine insomnia management: This bypasses evidence-based first-line treatments (CBT-I, ramelteon, low-dose doxepin) and exposes patients to unnecessary risks. 1, 8, 9

• Do not use trazodone doses >100 mg three times daily during benzodiazepine taper: Higher doses increase sedation risk without improving taper success. 6, 7

• Do not continue combination beyond 4 weeks: The evidence supports only short-term overlap during structured benzodiazepine discontinuation. 6, 7

• Do not ignore concurrent opioid use: This triples mortality risk and represents an absolute contraindication to benzodiazepine-trazodone combination. 4

• Do not prescribe in older adults with cardiovascular disease without fall-risk assessment: Trazodone alone causes significant orthostatic hypotension; adding benzodiazepines compounds this danger. 5